BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) received FDA approval for its experimental drug to be used as emergency treatment for swine flu sending the stock price soaring 98 cents to $10.65.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.